The importance of deep phenotyping PH registries with a focus on the PVRI-GoDeep registry.

Paul A Corris

doi:10.21542/gcsp.2020.12

Abstract

[No abstract. Showing first paragraph of article]Although pulmonary hypertension has long been recognised to complicate many common diseases, especially left-sided heart disease and lung disease, most basic, translational and clinical scientists together with the pharmaceutical industry have,to date, focused predominantly on pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension when developing effective treatments . Both entities are rare, leading to the erroneous belief that pulmonary hypertension in general is a rare condition, and not worthy of major global focus.

Highlights

Pulmonary hypertension has long been recognised to complicate many common diseases, especially left-sided heart disease and lung disease, most basic, translational and clinical scientists together with the pharmaceutical industry have, to date, focused predominantly on pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension when developing effective treatments[1]
Requests are to be decided by the PVRI-GoDeep Consortium/Use and Access Committee (UAC)
Combining several current registries to an inter-continental Meta-Registry provides substantial added scientific value: 1. It provides the most comprehensive approach to assess the global burden of PH by extrapolating ‘‘high quality’’ data from reference centers spotted around the world

Summary

INTRODUCTION

Pulmonary hypertension has long been recognised to complicate many common diseases, especially left-sided heart disease and lung disease, most basic, translational and clinical scientists together with the pharmaceutical industry have, to date, focused predominantly on pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension when developing effective treatments[1] Both entities are rare, leading to the erroneous belief that pulmonary hypertension in general is a rare condition, and not worthy of major global focus. There is a clear need to identify new druggable targets and discover new or repurpose existing therapies if we are going to meet patient’s expectations This is important in patients with pulmonary hypertension associated with pre-existing cardiovascular or chronic respiratory disease, where the majority of existing drugs were found to be ineffective or even exert adverse effects.

GLOBAL REGISTRY

ADDED SCIENTIFIC VALUE

Findings

CONCLUSIONS